Earnings

Sana Biotechnology Q3 Adj. EPS $(0.14) Beats $(0.15) Estimate

Nov 5, 2026 · 04:27 PM ET· updated 1h ago

Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 6.67 percent increase over losses of $(0.15) per share from

Why It Matters

Sana lost less money per share than experts thought it would. When a company that is still losing money does better than expected, it means the team is managing costs well.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

SANA2.41

-0.15 (-5.86%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.